The focus of this review is the ganglio-series of glycosphingolipids found in neuroblastoma (NB) and the myriad of unanswered questions associated with their possible role(s) in this cancer. NB is one of the more common solid malignancies of children. Five-year survival for those diagnosed with low risk NB is 90-95%, while that for children with high-risk NB is around 40-50%. Much of the survival rate reflects age of diagnosis with children under a year having a much better prognosis than those over two. Identification of expression of GD2 on the surface of most NB cells led to studies of the effectiveness and subsequent approval of anti-GD2 antibodies as a treatment modality. Despite much success, a subset of patients, possibly those whose tumors fail to express concentrations of gangliosides such as GD1b and GT1b found in tumors from patients with a good prognosis, have tumors refractory to treatment. These observations support discussion of what is known about control of ganglioside synthesis, and their actual functions in NB, as well as their possible relationship to treatment response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432824 | PMC |
| http://dx.doi.org/10.3390/ijms21155313 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Nat Commun
December 2024
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma.
View Article and Find Full Text PDFProspects of anti-GD2 immunotherapy for retinoblastoma.
Front Immunol
December 2024
Affiliated Hospital of Shandong Second Medical University,School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Article Synopsis
- - Retinoblastoma is the most common eye tumor in young children, and existing treatments like chemotherapy and surgery can have serious side effects, including blindness and toxic reactions.
- - Immunotherapy, especially targeting the GD2 sphingolipid found on retinoblastoma cells, shows promise due to its lower toxicity and potential to improve patient quality of life.
- - Anti-GD2 therapies, such as the monoclonal antibody Dinutuximab, CAR-T therapy, GD2 vaccines, and nanoparticles are emerging as effective treatments, but there are still challenges to overcome in their application.
Immunomodulatory properties of extracellular vesicles isolated from bone marrow of patients with neuroblastoma: role of PD-L1 and HLA-G.
Front Immunol
November 2024
UOSD Laboratorio di Terapie Cellulari, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Introduction: Extracellular vesicles (EVs) can be released by any cell and are crucial for cell-to-cell communications. EVs have been characterized in patients with solid and hematological tumors, where they play an important role in tumor progression and metastasis. EVs may express different surface proteins derived from the parental cells, including immunomodulatory molecules, such as HLA-G and PDL1.
View Article and Find Full Text PDFImmunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle.
Anticancer Res
November 2024
University of California Los Angeles, UCLA College of Letters & Science, Los Angeles, CA, U.S.A.
Article Synopsis
- The study reviews the use of anti-GD2-monoclonal antibodies (mAbs) in treating high-risk neuroblastoma through immunoliposomes (ILs) and specifically focuses on the characteristics, payloads, and preclinical data of GD2-ILs.
- A comprehensive search yielded 16 relevant references about GD2-ILs, which showed a consistent size around 124.8 nm and encapsulation efficiencies of approximately 66.2%.
- Experimental results indicated that GD2-ILs have selective targeting capabilities in mice models, indicating their potential for effective treatment with reduced toxicity in neuroblastoma patients.
GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target.
Cancer Genomics Proteomics
October 2024
The London Breast Institute, Princess Grace Hospital, London, U.K.
Expression of disialoganglioside GD2 in normal tissues is primarily limited to the central nervous system, peripheral sensory nerve fibers, dermal melanocytes, lymphocytes, and mesenchymal stem cells. Its widespread overexpression in various cancer types allows it to be classified as a tumor-associated antigen with potential diagnostic and therapeutic implications. This article reviews the synthesis pathways of GD2 and its role in cancer cell adhesion, proliferation, and metastasis with a focus on breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!